FiercePharma5h
Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate
The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...
FiercePharma7h
BioNTech inks settlements with NIH, UPenn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
FiercePharma7h
CRO Veeda unveils ‘modern and dynamic’ rebrand to mirror expansion into CDMO services
New year, new Veeda. The India-based CRO formerly known as Veeda Group has kicked off 2025 with a brand makeover.
FiercePharma9h
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
FiercePharma3h
Novo asks FDA to put kibosh on Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...
FiercePharma10h
Study sparks call for funding reforms to protect patient groups from pharma influence
Academics are calling for governments to act to “safeguard the ind | Academics are calling for governments to act to “safeguard the independence” of patient groups that receive funding from biopharma ...
FiercePharma9h
Astellas, Endo issue US drug recalls over empty capsule, ingredient concerns
Astellas Pharma and Endo subsidiary Endo USA issued voluntary recalls for products they manufacture over concerns of empty tablets and unapproved ingredients, respectively. | Astellas Pharma and Endo ...